| |  Online-Ressource |
|---|
| Verfasst von: | Würth, Roberto [VerfasserIn]  |
|---|
| | Donato, Elisa [VerfasserIn] |
|---|
| | Michel, Laura L. [VerfasserIn] |
|---|
| | Saini, Massimo [VerfasserIn] |
|---|
| | Becker, Lisa Maria [VerfasserIn] |
|---|
| | Cheytan, Tasneem [VerfasserIn] |
|---|
| | Dončević, Daria [VerfasserIn] |
|---|
| | Messmer, Tobias [VerfasserIn] |
|---|
| | Gutjahr, Ewgenija [VerfasserIn] |
|---|
| | Weber, Rebecca [VerfasserIn] |
|---|
| | Klein, Corinna [VerfasserIn] |
|---|
| | Alborzinia, Hamed [VerfasserIn] |
|---|
| | Yildiz, Umut [VerfasserIn] |
|---|
| | Vogel, Vanessa [VerfasserIn] |
|---|
| | Hlevnjak, Mario [VerfasserIn] |
|---|
| | Kozyulina, Polina [VerfasserIn] |
|---|
| | Neuberth, Sarah Jane [VerfasserIn] |
|---|
| | Schwerd-Kleine, Paul Albert Wolfgang [VerfasserIn] |
|---|
| | Jakab, Sevinç [VerfasserIn] |
|---|
| | Pfarr, Nicole [VerfasserIn] |
|---|
| | Angeles, Arlou Kristina J. [VerfasserIn] |
|---|
| | Laut, Astrid Karoline [VerfasserIn] |
|---|
| | Karpova, Darja [VerfasserIn] |
|---|
| | Falcone, Mattia [VerfasserIn] |
|---|
| | Hardt, Olaf [VerfasserIn] |
|---|
| | Theek, Benjamin [VerfasserIn] |
|---|
| | Wagner, Celina V. [VerfasserIn] |
|---|
| | Becker, Mirjam [VerfasserIn] |
|---|
| | Wagner, Sabine [VerfasserIn] |
|---|
| | Haselmayr, Martina [VerfasserIn] |
|---|
| | Schmitt, Anita [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Riethdorf, Sabine [VerfasserIn] |
|---|
| | Pantel, Klaus [VerfasserIn] |
|---|
| | Zapatka, Marc [VerfasserIn] |
|---|
| | Sültmann, Holger [VerfasserIn] |
|---|
| | Herrmann, Carl [VerfasserIn] |
|---|
| | Thewes, Verena [VerfasserIn] |
|---|
| | Lichter, Peter [VerfasserIn] |
|---|
| | Schneeweiss, Andreas [VerfasserIn] |
|---|
| | Sprick, Martin [VerfasserIn] |
|---|
| | Trumpp, Andreas [VerfasserIn] |
|---|
| Titel: | Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling |
|---|
| Verf.angabe: | Roberto Würth, Elisa Donato, Laura L. Michel, Massimo Saini, Lisa Becker, Tasneem Cheytan, Daria Doncevic, Tobias Messmer, Ewgenija Gutjahr, Rebecca Weber, Corinna Klein, Hamed Alborzinia, Umut Yildiz, Vanessa Vogel, Mario Hlevnjak, Polina Kozyulina, Sarah-Jane Neuberth, Paul Schwerd-Kleine, Sevinç Jakab, Nicole Pfarr, Arlou Kristina Angeles, Astrid K. Laut, Darja Karpova, Mattia Falcone, Olaf Hardt, Benjamin Theek, Celina V. Wagner, Mirjam Becker, Sabine Wagner, Martina Haselmayr, Anita Schmitt, Carsten Müller-Tidow, Sabine Riethdorf, Klaus Pantel, Marc Zapatka, Holger Sültmann, Carl Herrmann, Verena Thewes, Peter Lichter, Andreas Schneeweiss, Martin R. Sprick, Andreas Trumpp |
|---|
| E-Jahr: | 2025 |
|---|
| Jahr: | 03 January 2025 |
|---|
| Umfang: | 37 S. |
|---|
| Fussnoten: | Gesehen am 29.04.2025 |
|---|
| Titel Quelle: | Enthalten in: Nature cancer |
|---|
| Ort Quelle: | London : Nature Research, 2020 |
|---|
| Jahr Quelle: | 2025 |
|---|
| Band/Heft Quelle: | 6(2025), 1, Seite 67-85, [1-18] |
|---|
| ISSN Quelle: | 2662-1347 |
|---|
| Abstract: | Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently needed to effectively study disease progression and therapy responses. Here we present the establishment of long-term CTC-derived organoids from female individuals with metastatic breast cancer. Multiomics analysis of CTC-derived organoids along with preclinical modeling with xenografts identified neuregulin 1 (NRG1)-ERBB2 receptor tyrosine kinase 3 (ERBB3/HER3) signaling as a key pathway required for CTC survival, growth and dissemination. Genome-wide CRISPR activation screens revealed that fibroblast growth factor receptor 1 (FGFR1) signaling serves a compensatory function to the NRG1-HER3 axis and rescues NRG1 deficiency in CTCs. Conversely, NRG1-HER3 activation induced resistance to FGFR1 inhibition, whereas combinatorial blockade impaired CTC growth. The dynamic interplay between NRG1-HER3 and FGFR1 signaling reveals the molecular basis of cancer cell plasticity and clinically relevant strategies to target it. Our CTC organoid platform enables the identification and validation of patient-specific vulnerabilities and represents an innovative tool for precision medicine. |
|---|
| DOI: | doi:10.1038/s43018-024-00882-2 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1038/s43018-024-00882-2 |
|---|
| | Volltext: https://www.nature.com/articles/s43018-024-00882-2 |
|---|
| | DOI: https://doi.org/10.1038/s43018-024-00882-2 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Breast cancer |
|---|
| | Cancer |
|---|
| | Cancer models |
|---|
| | Mechanisms of disease |
|---|
| K10plus-PPN: | 1923807420 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling / Würth, Roberto [VerfasserIn]; 03 January 2025 (Online-Ressource)
